Fragment-Based Drug Discovery

Fragment-based drug discovery (FBDD) efforts are especially useful for identifying novel small-molecule drug leads against challenging targets such as protein-protein interactions (PPIs) and other ‘featureless’ proteins that lack traditional binding pockets. Entering its third decade, Cambridge Healthtech Institute’s Fragment-Based Drug Discovery conference highlights advancements in fragment-library design, biophysical screening technologies, and real-world case studies of fragment-to-lead success. It also explores emerging fragment applications such as for covalent-inhibitor discovery, activity-based protein profiling (ABPP), or as starting points for bifunctional degrader design in targeted protein-degradation approaches (TPD). Join fellow experts from both industry and academia to share insights, overcome challenges, and shape the next generation of fragment-based therapeutics.